Annovis Bio Reports Key Progress in Phase 3 Alzheimer’s and Parkinson’s Trials, Highlighting Buntanetap’s Potential

Annovis Bio Inc. (NYSE: ANVS) reported first-quarter 2026 business and financial results, highlighting continued advancement of its clinical-stage neurodegenerative disease programs. The company announced that its pivotal Phase 3 Alzheimer’s disease trial has reached 85% enrollment, with closure of enrollment to new participants after achieving sufficient screening levels to meet enrollment goals. Additionally, the Parkinson’s disease open-label extension study has reached 40% enrollment, alongside new biomarker initiatives and AI-powered digital monitoring, as Annovis continues advancing buntanetap toward potential regulatory submission.

The progress marks a significant milestone for Annovis, a Phase 3 clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The company’s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.

The announcement underscores the potential of buntanetap to transform treatment paradigms for Alzheimer’s and Parkinson’s diseases, which affect millions worldwide. The near-complete enrollment in the Alzheimer’s trial brings the company closer to pivotal data readouts that could support regulatory filings. For more details, the full press release is available at https://ibn.fm/M77X4.

Annovis’s progress also includes the integration of AI-powered digital monitoring and new biomarker initiatives, which could enhance trial efficiency and provide deeper insights into drug effects. These advancements are critical for neurodegenerative disease research, where objective biomarkers and sensitive outcome measures are often lacking. The company’s focus on multiple toxic proteins sets buntanetap apart from other therapies that target single pathways.

The successful enrollment and continued development of buntanetap are important for patients and investors alike, as they represent tangible steps toward addressing the high unmet need in Alzheimer’s and Parkinson’s diseases. If approved, buntanetap could offer a disease-modifying option that targets the root causes of neurodegeneration. For the latest news and updates relating to ANVS, visit the company’s newsroom at https://ibn.fm/ANVS.